Stay updated on Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Clinical Trial
Sign up to get notified when there's something new on the Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Clinical Trial page.

Latest updates to the Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now indicates recruitment has ended with 'No longer looking for participants' and adds user guidance sections such as 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study'. It also updates the 'Intervention/Treatment' header formatting and updates the page revision from v3.5.5 to v3.6.0.SummaryDifference0.4%

- Check19 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating a new build of the ClinicalTrials.gov page. This update does not modify the study details or visible content.SummaryDifference0.0%

- Check40 days agoChange DetectedRevision: v3.5.4 is now displayed, replacing Revision: v3.5.3, signaling a minor page update that does not alter the study data or displayed details.SummaryDifference0.0%

- Check61 days agoChange DetectedThe study record has been updated from an “Active, not recruiting” state to marked as **Completed**, with corresponding changes to key **actual** dates (including the study completion date) and refreshed record metadata such as last update/verification. The site version string also changed as part of the record update.SummaryDifference0.4%

- Check68 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded Mesangiocapillary glomerulonephritis, type II to the list of conditions.SummaryDifference0.0%

Stay in the know with updates to Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN Clinical Trial page.